SYK happens: AstraZeneca puts fostamatinib out of its misery
This article was originally published in Scrip
AstraZeneca is dropping fostamatinib, the first-in-class oral spleen tyrosine kinase (SYK) inhibitor, from development after disappointing clinical results in rheumatoid arthritis in two more Phase III trials. It is returning the rights to the compound to the originator, Rigel Pharmaceuticals, which is still contemplating its fate.
You may also be interested in...
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.
A couple of unexpected events for pimavanserin mean that Acadia will drop its development for major depressive disorder and have to wait a little longer to hear if it can launch the product for dementia-related psychosis, a large potential indication.